IARTIntegra LifeSciences Holdings Corporation shows mixed signals. While there are positive thematic elements, current fundamental and technical indicators suggest a neutral stance, requiring careful consideration of recent performance trends and upcoming earnings.
Integra LifeSciences operates in the medical technology sector, which benefits from an aging global population and increasing demand for advanced medical solutions. However, its specific product focus might face competition and evolving healthcare regulations.
The company's recent financial performance shows declining revenue and net losses, impacting profitability and valuation metrics. Debt levels have increased, and free cash flow has been volatile.
The stock price is trading below its 52-week range and has experienced significant declines over the past year. Current technical indicators are mixed, with some suggesting potential for a short-term bounce but overall trend remaining bearish.
| Factor | Score |
|---|---|
| Aging Global Population | 85 |
| Healthcare Innovation | 75 |
| Competitive Landscape | 55 |
| Regulatory Environment | 60 |
| Economic Sensitivity | 65 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 20 |
| Growth | 60 |
| Balance Sheet Health | 50 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Support & Resistance | 65 |
| Moving Averages | 40 |
| Volume Confirmation | 70 |
Positive EPS Surprise
The company has a history of beating EPS estimates, with recent quarters showing positive surprises (e.g., +13.34% in Q1 2025, +5.28% in Q4 2024).
Attractive Price-to-Sales Ratio
The Price-to-Sales (PS) ratio of 0.8 for TTM suggests the company is valued relatively low compared to its revenue.
Negative EPS Growth
EPS TTM is negative (-0.38), indicating the company is currently unprofitable on a per-share basis over the last twelve months.
High Price-to-Sales for Negative Earnings
Despite a low PS ratio of 0.8, the company has a negative TTM net income, resulting in a very high (or negative) P/E ratio, indicating it's not currently a value investment based on earnings.
July 2025
31
Next Earnings Date
H: $0.46
A: $0.43
L: $0.42
H: 399.08M
A: 395.06M
L: 386.40M
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
15.88 USD
The 39 analysts offering 1 year price forecasts for IART have a max estimate of 30.00 and a min estimate of 10.00.